Quality Audit Success
Piramal Pharma Solutions Reports Strong Performance in Over 200 Customer Audits and Regulatory Approvals
Anonymous
Piramal Pharma Solutions (PPS), a global contract drug manufacturer, cleared more than 200 customer audits and received over 70 regulatory approvals in its last fiscal year, the company announced on June 22, 2026. The results signal a major quality milestone for one of India's largest CDMOs — companies that make drugs on behalf of other pharmaceutical firms — as it competes for contracts shifting away from China. PR Newswire reported the announcement.
The numbers came alongside a broader quality push that includes AI-driven tools, deviation-reduction programs, and 38 regulatory inspections successfully closed in FY26 alone, according to The Tribune. Chief Quality Officer Rashida Najmi said the strategy combines "robust governance, quality culture, and digital transformation" to keep the company in sustained compliance.
How PPS Built Its Audit-Ready Quality Machine
PPS uses a three-tier quality governance structure. Crucially, this structure reports independently from manufacturing operations — meaning quality teams cannot be pressured by production teams to cut corners. The company also runs a program called RESOLVE, short for REsolute to SOLVE Deviations, which focuses on getting manufacturing and lab work right the first time. Fewer errors mean fewer costly batch failures and fewer delays before regulators, PR Newswire reported.
On the digital side, PPS deployed tools including iAssist, an AI-enabled investigation tool, and platforms called eLab and exForms to cut manual errors. According to internal technology reports cited by research analysts, automation has reduced manual intervention by up to 90% at certain facilities, while AI-driven analytics have cut waste in quality assurance by 30 to 50%.
FDA Inspections Show a Rocky Then Clean Road to Compliance
The path to PPS's current "Zero OAI" status — meaning no site currently faces Official Action from the US FDA — was not entirely smooth. In February 2025, the FDA issued six observations at PPS's Navi Mumbai facility. Then in February 2026, the Digwal plant in Telangana received four more observations. The company responded quickly to both. Market Screener noted the Digwal plant received a formal Establishment Inspection Report from the FDA in May 2026, signaling full compliance and closure of the case.
The clean Digwal outcome matters for the bottom line. The site holds 750 kL of production capacity, and its cleared status allows uninterrupted drug exports to the US and UK markets. Separately, PPS's Grangemouth facility in the UK delivered its 1,500th batch of ADCs — antibody-drug conjugates used in cancer treatment — in March 2026, underscoring the company's foothold in high-value oncology drugs.
BIOSECURE Act Tailwinds Drive Demand for Indian CDMOs
PPS's audit performance arrives at a strategically important moment. The US BIOSECURE Act, passed in late 2024, restricts American drug companies from working with certain Chinese manufacturers like WuXi Biologics. That has pushed Western biotechs to seek alternative partners fast. Indian CDMOs like PPS have invested heavily in audit readiness to win that business. PPS also announced a $90 million expansion of its Lexington, Kentucky and Riverview, Michigan facilities to boost sterile injectable and ADC capacity, according to Cochrane Times Post.
COO Herve Berdou has led operational initiatives at PPS, including a project execution system called the POD Method — Plan, Own, Deliver — rolled out at the Aurora, Canada facility in October 2025 to cut project delays and quality deviations. Chairperson Nandini Piramal has framed FY27 as a "return to growth" year, with the company targeting $2 billion in revenue by FY30.
Strong Audits Contrast With a Financially Muted Year
The quality wins sit alongside a harder financial story. PPS posted total revenue of ₹8,869 crores in FY26, but net profit took a hit from ₹176 crores in exceptional impairment losses. Revenue fell roughly 3% year over year. Analysts at ICICI Direct called the year "below estimates," pointing to a 32% drop in EBITDA and heavy inventory destocking by one large commercial customer, according to Ontario Farmer.
Still, the same analysts say the quality track record is a critical "de-risker" for winning future contracts. In CDMO deal negotiations, 92% of sponsors now prioritize digital connectivity and data transparency, according to industry forecasts. PPS's clean audit record and digital tool investments position it to compete for that pipeline — even if the financial recovery takes more time to show up in earnings.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
7
Articles
7
Reach
7
A
AnonymousAuthor
